Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

Cancer

Volumn 92, Issue 11, 2001, Pages 2902-2910

  Kosmas, Christos ^a   Tsavaris, Nicolas ^b   Vadiaka, Maria ^b   Stavroyianni, Niki ^b   Koutras, Angelos ^c   Malamos, Nikolaos ^a   Onyenadum, Adimchi ^c   Rokana, Sofia ^a   Polyzos, Aristidis ^b   Kalofonos, Haralambos P ^c  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Docetaxel; Gemcitabine; Nonsmall cell lung carcinoma; Paclitaxel

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERANCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LARGE CELL CARCINOMA; LEUKOCYTE COUNT; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PATIENT COMPLIANCE; PLATINUM; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0035576009     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011201)92:11<2902::AID-CNCR10103>3.0.CO;2-O     Document Type: Article

References (36)

1. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
2. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
3. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vindesine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
4. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
5. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer
6. Phase II study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer
7. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
8. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a Phase II multicenter trial
9. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer
10. Salvage therapy with gemcitabine in advanced non-small cell lung cancer progressing after prior carboplatin-paclitaxel
11. Gemcitabine as second-line treatment for advanced non-small ceil lung cancer: A Phase II trial
12. A Phase II study of paclitaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer
13. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
14. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: Preliminary results
15. Phase I study of dose escalated paclitaxel, ifosfamide, and cisplatin combination chemotherapy in advanced solid tumours
16. Non-parametric estimation from incomplete observations
17. Optimal two-stage designs for phase II clinical trials
18. Combination chemotherapy versus single agents followed by combination chemotheraphy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group
19. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A Phase II trial
20. A Phase II study of docetaxel in patients with paclitaxel-resistant breast cancer
21. Activity of gemcitabine in cisplatin-pretreated patients with advanced non-small cell lung cancer: A Phase II trial
22. Gemcitabine in platinum treated non-small cell lung cancer
23. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere
24. Bcl2 is the guardian of microtubule integrity
25. Taxotere is an active drug in non small cell lung cancer: A Phase II trial of the EORTC Early Clinical Trials Group (ECTG)
26. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
27. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
28. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter Phase II study
29. Docetaxel (Taxotere) plus cisplatin: An active and well-tolerated combination in patients with advanced non-small cell lung cancer
30. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
31. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome
32. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens
33. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
34. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter Phase II trial
35. A novel administration of gemcitabine (via constant dose rate) in combination with docetaxel in advanced non-small cell lung cancer
36. A Phase II study of docetaxel and gemcitabine combination in patients with non-small cell lung cancer